Macular oedema treatment to be available on PBS

macular degeneration - closeup on eye with lots of high tech crosshairs
A government subsidy for a biologic to treat vision impairment caused by macular oedema in patients with diabetes or retinal vein occlusion (branch or central) will be available from 1 July. Professor Paul Mitchell, Head of Ophthalmology at Sydney’s Westmead Hospital welcomed the listing of Lucentis (ranibizumab) on the PBS for patients experiencing vision loss

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous CMA calls for less health red tape, more innovation support
Next Don't mandate country of origin labelling: ASMI